Future studies will show whether over-expression of the transporter and eventually others of the family in therapy sensitive tumor cells, activate the NFκB pathway and whether this might contribute to a more aggressive growth of multiple drug resistant cancers. The gene discussed is NFKB1; the disease is cancer.